The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model

被引：9

作者：

Xu, Yunze ^{[1
,2
]}

Zhu, Qi ^{[1
]}

Chen, Dongning ^{[1
]}

Shen, Zhoujun ^{[1
]}

Wang, Weiqing ^{[3
]}

Ning, Guang ^{[3
]}

Zhu, Yu ^{[1
]}

机构：

[1] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Urol, Shanghai 200025, Peoples R China

[2] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Urol, Shanghai 200025, Peoples R China

[3] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Endocrinol,Clin Ctr Shanghai Endocrine & Met, Shanghai 200025, Peoples R China

来源：

TUMOR BIOLOGY | 2015年 / 36卷 / 07期

基金：

中国国家自然科学基金;

关键词：

Pheochromocytoma; Heat shock protein 90; 17-Allylamino-17-demethoxygeldanamycin; Xenograft model; BREAST-CANCER; PHASE-II; 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN; PATHWAYS; TRIAL; CELLS;

D O I：

10.1007/s13277-015-3162-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This study aims to investigate the effect of heat shock protein 90 (HSP90) inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) in the malignant pheochromocytoma using a xenograft mouse model. Treatment with 17-AAG induced a marked reduction in the volume and weight of PC12 pheochromocytoma cell tumor xenografts in mice. Furthermore, 17-AAG also significantly inhibited the expression of HSP90 and its client proteins. Our results validated HSP90 as an important target in pheochromocytoma and provided rationale for the testing of HSP90 inhibitors as a promising therapeutic agent in the antitumor therapy of pheochromocytoma.

引用

页码：5103 / 5108

页数：6

共 50 条

[1] Effects of the HSP90 inhibitor 17-AAG in glioblastoma multiforme
Sauvageot, C.
Barnes, J.
Weatherbee, J.
Ramakrishna, N.
Kesari, S.
Stiles, C.
Kieran, M.
Wen, P.
NEURO-ONCOLOGY, 2006, 8 (04) : 417 - 417
[2] The HSP90 inhibitor 17-AAG potentiates the antileishmanial activity of the ether lipid edelfosine
Varela-M, Ruben E.
Mollinedo-Gajate, Cristina
Muro, Antonio
Mollinedo, Faustino
ACTA TROPICA, 2014, 131 : 32 - 36
[3] Alleviating neurodegeneration by an anticancer agent - An Hsp90 inhibitor (17-AAG)
Waza, Masahiro
Adachi, Hiroaki
Katsuno, Masahisa
Minamiyama, Makoto
Tanaka, Fumiaki
Sobue, Gen
INTEGRATED MOLECULAR MEDICINE FOR NEURONAL AND NEOPLASTIC DISORDERS, 2006, 1086 : 21 - 34
[4] Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment
Talaei, Sona
Mellatyar, Hassan
Asadi, Asadollah
Akbarzadeh, Abolfazl
Sheervalilou, Roghayeh
Zarghami, Nosratollah
CHEMICAL BIOLOGY & DRUG DESIGN, 2019, 93 (05) : 760 - 786
[5] HSP90 Inhibitor 17-AAG Selectively Eradicates Lymphoma Stem Cells
Newman, Bryan
Liu, Yan
Lee, Hsiu-Fang
Sun, Duxin
Wang, Yin
CANCER RESEARCH, 2012, 72 (17) : 4551 - 4561
[6] 17-AAG, an Hsp90 inhibitor, causes kinetochore defects: a novel mechanism by which 17-AAG inhibits cell proliferation
Y Niikura
S Ohta
K J Vandenbeldt
R Abdulle
B F McEwen
K Kitagawa
Oncogene, 2006, 25 : 4133 - 4146
[7] 17-AAG, an Hsp90 inhibitor, causes kinetochore defects: a novel mechanism by which 17-AAG inhibits cell proliferation
Niikura, Y.
Ohta, S.
Vandenbeldt, K. J.
Abdulle, R.
McEwen, B. F.
Kitagawa, K.
ONCOGENE, 2006, 25 (30) : 4133 - 4146
[8] Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance
O'Malley, Katherine J.
Langmann, Gabrielle
Ai, Junkui
Ramos-Garcia, Raquel
Vessella, Robert L.
Wang, Zhou
PROSTATE, 2012, 72 (10): : 1117 - 1123
[9] 17-AAG, an Hsp90 inhibitor, suppress hepatitis C virus (HCV) replication
Ujino, Saneyuki
Shimotohno, Kunitada
Takaku, Hiroshi
ANTIVIRAL RESEARCH, 2007, 74 (03) : A62 - A63
[10] MEK Inhibition Potentiates the Activity of Hsp90 Inhibitor 17-AAG against Pancreatic Cancer Cells
Zhang, Tao
Li, Yanyan
Zhu, Zhenkun
Gu, Mancang
Newman, Bryan
Sun, Duxin
MOLECULAR PHARMACEUTICS, 2010, 7 (05) : 1576 - 1584

← 1 2 3 4 5 →